nirsevimab
Marketedupdated 2mo agoby Sanofi-Aventis US LLC
Approvedcommunity read0 votes
Antibody drug with a maximum clinical stage of Approval (across all indications), with 3 approved and 1 investigational indication.
all catalysts(5)
approval · 5
Jul 17, 2023
approval
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Feb 23, 2024
approval
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Aug 22, 2024
approval
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Oct 20, 2025
approval
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
Apr 7, 2026
approval
BEYFORTUS (NIRSEVIMAB-ALIP) — FDA approval
nirsevimab
→
News(0)
no news has mentioned this drug yet
comments(0)
5-min edit window · permanent after that